Natixis Advisors Reduces $7M in Cardinal Health, Inc. ($CAH)
Natixis Advisors has reduced its stake in Cardinal Health by 5.45%, according to its latest 13F filing.
Key Points
- Natixis Advisors trimmed its Cardinal Health holdings by 28,419 shares, reducing its stake by 5.45% to 492,832 shares as of the latest period.
- Cardinal Health trades at $221.77 per share with a market cap of approximately $51.94 billion and a P/E ratio of 33.91.
- Insiders have been active, with recent sales by executives, and analysts maintain positive ratings with price targets up to $258.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Natixis Advisors has reduced its holdings in Cardinal Health, Inc. (NYSE: CAH) by 28,419 shares, a 5.45% decrease according to its recent filing with the SEC. As of the filing, the firm held 492,832 shares valued at about $109.3 million.
Natixis Advisors vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
What Changed in Natixis Advisors' Cardinal Health Position
Natixis Advisors trimmed its stake in Cardinal Health from 521,251 shares to 492,832 shares, a reduction of 28,419 shares. This represents a 5.45% decrease in their holdings, reflecting a strategic adjustment in their investment portfolio.
Other Institutional Activity in Cardinal Health
Several other institutional investors have also adjusted their positions in Cardinal Health. BlackRock, Inc. reduced its holdings by 146,765 shares, ending with 28,494,855 shares valued at approximately $6.02 billion. Vanguard Capital Management LLC and Vanguard Portfolio Management LLC both increased their stakes significantly, each adding over 13 million shares to their portfolios. State Street Corp decreased its position by 434,712 shares, holding 12,074,518 shares worth around $2.55 billion. Meanwhile, Geode Capital Management, LLC slightly increased its stake by 51,519 shares, totaling 6,580,532 shares valued at $1.39 billion.
Cardinal Health, Inc. Stock Up 1.3%
Shares of Cardinal Health are trading at $221.77. The company boasts a market capitalization of about $51.94 billion and a P/E ratio of 33.91. Its forward P/E stands at 18.49, with a beta of 0.526. The stock's 52-week range has been between $137.75 and $233.60, with a 50-day moving average of $203.73 and a 200-day moving average of $197.28.
$CAH stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
Cardinal Health reported revenue of approximately $250.74 billion with a revenue growth rate of 11%. The company's net margin is 0.62%, and its return on equity is notable. Earnings per share came in at $6.54. The next earnings report is expected on August 18, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
2 target raises vs 2 cuts.
-
EPS & revenue
EPS beat estimates by 12.6%. Revenue missed estimates by 2.2%.
-
Profit surprise
EBITDA missed by 27 percent. Operating income missed by 46 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
2 target raises, 2 target cuts.
-
Earnings quality
Positive free cash flow.
Earnings Call Summary
Cardinal Health reported first quarter revenue of $60.9 billion, up 22 percent year over year, with earnings per share of $3.17 beating consensus of $2.80. The company saw broad strength across all five business segments, particularly in pharmaceutical specialty solutions where profit grew 26 percent and specialty drug sales benefited from GLP-1 demand growth. The strong quarter reflected execution on strategy, successful integration of acquisitions, and robust underlying pharmaceutical utilization trends across the market.
Guidance Cardinal Health raised its full year earnings guidance to between $9.65 and $9.85 per share, up 35 cents from prior guidance. The company expects Pharma profit to grow 16 to 19 percent for the year, driven by strong drug demand and the Solaris Health acquisition closing soon. Free cash flow is now guided to $3 billion to $3.5 billion for the full year, up from prior range.
Clearly negative report. The company missed important expectations and likely triggers downward revisions.
Dividend
Cardinal Health offers an annual dividend rate of $2.05, yielding 0.9% with a payout ratio of 31.19%. This provides an attractive option for income-focused investors.
Insider Buying and Selling at Cardinal Health, Inc.
Insider activity has been notable, with Patricia Hemingway Hall purchasing 381 shares at $207.83 on April 15, 2026. Meanwhile, Michelle Greene, the Chief Information Officer, sold 2,746 shares at an average price of $228.47 on February 27, 2026. Aaron Alt, the Chief Financial Officer, sold a total of 6,570 shares across several transactions in February 2026, with prices ranging around $225.50.
Analysts Set New Price Targets
On May 4, 2026, JP Morgan maintained a 'hold' rating on Cardinal Health with a price target of $215. Citigroup and TD Cowen both maintained 'buy' ratings with targets of $245 and $255 respectively on May 1, 2026. The consensus among analysts is a 'strong buy', with a mean target price of $245.27 from 15 opinions.
About Cardinal Health
Cardinal Health, Inc. is a healthcare services and products company based in Dublin, Ohio. It operates in the Pharmaceutical and Specialty Solutions and Global Medical Products and Distribution segments. The company provides solutions for hospitals, pharmacies, and other healthcare providers, distributing a wide range of medical and pharmaceutical products. With over 53,000 employees, Cardinal Health is a key player in the healthcare distribution sector.
Bottom Line
Natixis Advisors' recent reduction in Cardinal Health shares is part of a broader trend of institutional adjustments. Cardinal Health remains a significant player in the healthcare industry, with its stock trading near the upper end of its 52-week range. Investors should note that 13F filings are historical and may not reflect current positions.
Get Cardinal Health, Inc. alerts
New 13F filings, insider trades, and analyst moves on $CAH, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.